Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Randomised double-blind placebo-controlled crossover trial of diamorphine by implantable drug delivery system in the treatment of chronic non-malignant pain
ISRCTN ISRCTN45019882
ClinicalTrials.gov identifier
Public title Randomised double-blind placebo-controlled crossover trial of diamorphine by implantable drug delivery system in the treatment of chronic non-malignant pain
Scientific title
Acronym N/A
Serial number at source N0557115189
Study hypothesis Do implanted intrathecal analgesic drug pumps relieve pain in patients with chronic non-malignant pain?
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised double-blind placebo-controlled crossover
Countries of recruitment United Kingdom
Disease/condition/study domain Signs and Symptoms: Pain
Participants - inclusion criteria Aim to recruit 16 patients to the trial from patients scheduled for intrathecal pump implantation for the delivery of diamorphine in the management of chronic non-cancer pain.
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/09/2002
Anticipated end date 30/04/2004
Status of trial Completed
Patient information material
Target number of participants 16
Interventions 1. Pump filled with diamorphine in normal saline set initially to deliver 0.5 ml/day (0.1 ml)
2. Pump filled with normal saline and set initially to deliver 0.1 ml per day

For the first 2 weeks the pump can be increased by 0.05 ml/day at half-weekly reviews if the patient describes inadequate pain relief. The pump rate will remain constant for the next 4 weeks and be returned to 0.1 ml/day by week 8 (in half-weekly intervals by increments of 0.05 ml/day). The pump is then refilled with the alternative mixture and the process repeated, ending with 0.1 ml/day by week 8 of the second pump refill (week 16).
Primary outcome measure(s) 1. Pain relief by Visual Analogue Scale (VAS)
2. Function by Oswestry Disability Score
3. Psychological parameters by Hospital Anxiety Depression Score
4. Pain Coping Strategies Questionnaire
5. Sociological factors by Short Form-36 Questionnaire
6. Overall Assessment by Global Impression of Change
Secondary outcome measure(s) Not provided at time of registration
Sources of funding The Dudley Group of Hospitals NHS Trust (UK)
Trial website
Publications
Contact name Dr  Jonathan  Raphael
  Address Consultant in Pain Management
Guest Hospital
Tipton Road
  City/town Dudley
  Zip/Postcode DY1 4SE
  Country United Kingdom
  Tel +44 (0)1384 244809
  Fax +44 (0)1384 244808
  Email JH.Raphael@dgoh.nhs.uk
Sponsor Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)207 307 2622
  Fax +44 (0)207 307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.doh.gov.uk
Date applied 12/09/2003
Last edited 05/05/2010
Date ISRCTN assigned 12/09/2003
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central